L'adénome peut-il causer des problèmes cardiaques ?
Oui, l'excès de GH peut entraîner des cardiomyopathies et d'autres problèmes cardiovasculaires.
CardiomyopathiesProblèmes cardiovasculairesHormone de croissance
#3
Y a-t-il un risque accru de diabète ?
Oui, l'adénome à GH peut provoquer une résistance à l'insuline, augmentant le risque de diabète.
DiabèteRésistance à l'insulineAdénome hypophysaire
#4
Les troubles psychologiques sont-ils fréquents ?
Oui, des troubles comme l'anxiété et la dépression peuvent être des complications de l'adénome.
Troubles psychologiquesAnxiétéDépression
#5
Comment les complications sont-elles gérées ?
Les complications sont gérées par un suivi médical régulier et des traitements adaptés selon les symptômes.
Gestion des complicationsSuivi médicalTraitements
Facteurs de risque
5
#1
Quels sont les principaux facteurs de risque ?
Les facteurs incluent des antécédents familiaux, des troubles endocriniens et des mutations génétiques.
Facteurs de risqueAntécédents familiauxMutations génétiques
#2
L'âge influence-t-il le risque d'adénome ?
Oui, le risque augmente généralement chez les adultes d'âge moyen, mais peut survenir à tout âge.
ÂgeRisqueAdénome hypophysaire
#3
Les hommes sont-ils plus à risque ?
Non, les hommes et les femmes sont également touchés par les adénomes à GH.
SexeRisqueAdénome hypophysaire
#4
Les maladies endocriniennes augmentent-elles le risque ?
Oui, des maladies comme la maladie de Cushing ou des syndromes génétiques peuvent augmenter le risque.
Maladies endocriniennesSyndromes génétiquesRisque
#5
Le mode de vie influence-t-il le risque d'adénome ?
Un mode de vie sain peut réduire le risque, mais des facteurs génétiques jouent un rôle plus important.
Mode de vieRisqueFacteurs génétiques
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Adénome hypophysaire à GH : Questions médicales les plus fréquentes",
"headline": "Adénome hypophysaire à GH : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Adénome hypophysaire à GH : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-26",
"dateModified": "2025-03-23",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Adénome hypophysaire à GH"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs de l'hypophyse",
"url": "https://questionsmedicales.fr/mesh/D010911",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de l'hypophyse",
"code": {
"@type": "MedicalCode",
"code": "D010911",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C19.700.734"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Adénome hypophysaire à GH",
"alternateName": "Growth Hormone-Secreting Pituitary Adenoma",
"code": {
"@type": "MedicalCode",
"code": "D049912",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Yao Zhao",
"url": "https://questionsmedicales.fr/author/Yao%20Zhao",
"affiliation": {
"@type": "Organization",
"name": "Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China."
}
},
{
"@type": "Person",
"name": "Cheol Ryong Ku",
"url": "https://questionsmedicales.fr/author/Cheol%20Ryong%20Ku",
"affiliation": {
"@type": "Organization",
"name": "Pituitary Tumor Center, Severance Hospital, Seoul, Korea."
}
},
{
"@type": "Person",
"name": "Eun Jig Lee",
"url": "https://questionsmedicales.fr/author/Eun%20Jig%20Lee",
"affiliation": {
"@type": "Organization",
"name": "Pituitary Tumor Center, Severance Hospital, Seoul, Korea."
}
},
{
"@type": "Person",
"name": "John D Carmichael",
"url": "https://questionsmedicales.fr/author/John%20D%20Carmichael",
"affiliation": {
"@type": "Organization",
"name": "USC Brain Tumor Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA."
}
},
{
"@type": "Person",
"name": "Gabriel Zada",
"url": "https://questionsmedicales.fr/author/Gabriel%20Zada",
"affiliation": {
"@type": "Organization",
"name": "USC Brain Tumor Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Giant growth hormone-secreting pituitary adenomas from the endocrinologist's perspective.",
"datePublished": "2022-11-01",
"url": "https://questionsmedicales.fr/article/36318446",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12020-022-03241-2"
}
},
{
"@type": "ScholarlyArticle",
"name": "Global changes in chromatin accessibility and transcription in growth hormone-secreting pituitary adenoma.",
"datePublished": "2022-08-10",
"url": "https://questionsmedicales.fr/article/35947334",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12020-022-03155-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Effect and Potential Mechanism Analysis of Growth Hormone-Secreting Pituitary Adenomas on Thyroid Function.",
"datePublished": "2023-05-20",
"url": "https://questionsmedicales.fr/article/37217118",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.eprac.2023.05.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Uric acid levels correlate with disease activity in growth hormone-secreting pituitary adenoma patients.",
"datePublished": "2023-09-25",
"url": "https://questionsmedicales.fr/article/37818085",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2023.1230852"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cost-effectiveness of direct surgery versus preoperative octreotide therapy for growth-hormone secreting pituitary adenomas.",
"datePublished": "2022-08-27",
"url": "https://questionsmedicales.fr/article/36030360",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11102-022-01270-8"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies endocriniennes",
"item": "https://questionsmedicales.fr/mesh/D004700"
},
{
"@type": "ListItem",
"position": 3,
"name": "Maladies de l'hypophyse",
"item": "https://questionsmedicales.fr/mesh/D010900"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs de l'hypophyse",
"item": "https://questionsmedicales.fr/mesh/D010911"
},
{
"@type": "ListItem",
"position": 5,
"name": "Adénome hypophysaire à GH",
"item": "https://questionsmedicales.fr/mesh/D049912"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Adénome hypophysaire à GH - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Adénome hypophysaire à GH",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-14",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Adénome hypophysaire à GH",
"description": "Comment diagnostiquer un adénome à GH ?\nQuels tests sont utilisés pour évaluer la GH ?\nQuels symptômes indiquent un adénome à GH ?\nL'IRM est-elle nécessaire pour le diagnostic ?\nPeut-on diagnostiquer sans symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Adénome hypophysaire à GH",
"description": "Quels sont les signes de l'acromégalie ?\nComment l'adénome à GH affecte-t-il le métabolisme ?\nQuels troubles visuels peuvent survenir ?\nY a-t-il des symptômes psychologiques associés ?\nLes femmes sont-elles plus touchées par ces symptômes ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Adénome hypophysaire à GH",
"description": "Peut-on prévenir un adénome hypophysaire ?\nLes antécédents familiaux augmentent-ils le risque ?\nY a-t-il des habitudes de vie à adopter ?\nLes examens réguliers sont-ils importants ?\nLe stress influence-t-il le développement d'adénomes ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Adénome hypophysaire à GH",
"description": "Quels traitements sont disponibles pour l'adénome à GH ?\nLa chirurgie est-elle toujours nécessaire ?\nQuels médicaments sont utilisés pour traiter l'adénome ?\nLa radiothérapie est-elle efficace ?\nQuels sont les effets secondaires des traitements ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Adénome hypophysaire à GH",
"description": "Quelles complications peuvent survenir ?\nL'adénome peut-il causer des problèmes cardiaques ?\nY a-t-il un risque accru de diabète ?\nLes troubles psychologiques sont-ils fréquents ?\nComment les complications sont-elles gérées ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Adénome hypophysaire à GH",
"description": "Quels sont les principaux facteurs de risque ?\nL'âge influence-t-il le risque d'adénome ?\nLes hommes sont-ils plus à risque ?\nLes maladies endocriniennes augmentent-elles le risque ?\nLe mode de vie influence-t-il le risque d'adénome ?",
"url": "https://questionsmedicales.fr/mesh/D049912#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer un adénome à GH ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins pour mesurer les niveaux de GH et d'IGF-1, ainsi que l'imagerie par résonance magnétique (IRM)."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer la GH ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de stimulation et de suppression de la GH, ainsi que des dosages d'IGF-1, sont couramment utilisés."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un adénome à GH ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent acromégalie, maux de tête, troubles visuels et fatigue excessive."
}
},
{
"@type": "Question",
"name": "L'IRM est-elle nécessaire pour le diagnostic ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'IRM est essentielle pour visualiser la tumeur et évaluer sa taille et son impact sur les structures environnantes."
}
},
{
"@type": "Question",
"name": "Peut-on diagnostiquer sans symptômes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains adénomes sont découverts accidentellement lors d'examens pour d'autres raisons."
}
},
{
"@type": "Question",
"name": "Quels sont les signes de l'acromégalie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent une croissance des mains, des pieds, des traits faciaux grossis et des douleurs articulaires."
}
},
{
"@type": "Question",
"name": "Comment l'adénome à GH affecte-t-il le métabolisme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il provoque une résistance à l'insuline, une augmentation de la masse musculaire et des troubles lipidiques."
}
},
{
"@type": "Question",
"name": "Quels troubles visuels peuvent survenir ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles visuels comme la vision floue ou la perte de vision périphérique peuvent se produire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes psychologiques associés ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes comme l'anxiété, la dépression et des changements d'humeur peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus touchées par ces symptômes ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'adénome à GH affecte les hommes et les femmes de manière égale, mais les symptômes peuvent varier."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir un adénome hypophysaire ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de méthode de prévention spécifique, mais un suivi médical régulier est conseillé."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux augmentent-ils le risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de troubles endocriniens peuvent augmenter le risque d'adénomes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des habitudes de vie à adopter ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Maintenir un mode de vie sain, avec une alimentation équilibrée et de l'exercice, peut aider."
}
},
{
"@type": "Question",
"name": "Les examens réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent aider à détecter précocement des anomalies hormonales."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il le développement d'adénomes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress peut affecter la santé hormonale, mais son lien direct avec les adénomes n'est pas prouvé."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour l'adénome à GH ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent la chirurgie, la radiothérapie et des médicaments comme les analogues de la somatostatine."
}
},
{
"@type": "Question",
"name": "La chirurgie est-elle toujours nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas toujours, la décision dépend de la taille de la tumeur et des symptômes. Les médicaments peuvent suffire."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter l'adénome ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les analogues de la somatostatine et les antagonistes de la GH sont couramment prescrits."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle efficace ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut réduire la taille de la tumeur et contrôler la sécrétion de GH, mais elle prend du temps."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires des traitements ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des nausées, des douleurs au site d'injection et des troubles hormonaux."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des troubles visuels, des maux de tête chroniques et des déséquilibres hormonaux."
}
},
{
"@type": "Question",
"name": "L'adénome peut-il causer des problèmes cardiaques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'excès de GH peut entraîner des cardiomyopathies et d'autres problèmes cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il un risque accru de diabète ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'adénome à GH peut provoquer une résistance à l'insuline, augmentant le risque de diabète."
}
},
{
"@type": "Question",
"name": "Les troubles psychologiques sont-ils fréquents ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles comme l'anxiété et la dépression peuvent être des complications de l'adénome."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont gérées par un suivi médical régulier et des traitements adaptés selon les symptômes."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des troubles endocriniens et des mutations génétiques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque d'adénome ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque augmente généralement chez les adultes d'âge moyen, mais peut survenir à tout âge."
}
},
{
"@type": "Question",
"name": "Les hommes sont-ils plus à risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les hommes et les femmes sont également touchés par les adénomes à GH."
}
},
{
"@type": "Question",
"name": "Les maladies endocriniennes augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme la maladie de Cushing ou des syndromes génétiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il le risque d'adénome ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un mode de vie sain peut réduire le risque, mais des facteurs génétiques jouent un rôle plus important."
}
}
]
}
]
}
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China.
Shanghai Key Laboratory of Brain Function Restoration and Neural Regeneration, Shanghai, China.
National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Sate Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai, China.
National Center for Neurological Disorders, Shanghai, China.
Neurosurgical Institute of Fudan University, Fudan University, Shanghai, China.
Department of Neurosurgery, Huashan Hospital, Shanghai Medical College, Fudan University, National Center for Neurological Disorders, Shanghai, China. yezhaozj663812@126.com.
Shanghai Clinical Medical Center of Neurosurgery, Shanghai, China. yezhaozj663812@126.com.
Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; China Pituitary Disease Registry Center, Chinese Pituitary Adenoma Cooperative Group, Beijing, China.
Since giant (≥40 mm) GH-secreting pituitary adenomas are rarely encountered, data on their characteristics and treatment outcomes are limited. We aimed to investigate the characteristics of giant GH-s...
We have evaluated 15 (six female/nine male) and 57 (29 female/28 male) patients with acromegaly in giant and <40 mm adenoma groups, respectively. Patients with <40 mm adenoma were further divided into...
In giant adenoma group, median (IQR) preoperative maximal diameter of adenoma was 40 mm (5 mm), median preoperative GH level was 40 (153.4) ng/mL and median baseline IGF-1 level was 2.19 (1.88) × ULN ...
Hormonal remission rates of acromegaly patients with ≥20 mm pituitary macroadenoma were comparable. However, giant GH-secreting pituitary adenomas require an aggressive multimodal treatment approach....
Growth hormone-secreting pituitary adenoma (GHPA) is an insidious disease with persistent hypersecretion of growth hormone and insulin-like growth factor 1, causing increased morbidity and mortality. ...
Six patients diagnosed with GHPA in the Department of Neurosurgery at Huashan Hospital were enrolled in our study. Primary pituitary adenoma tissues and adjacent normal pituitary specimens with no mor...
Totally, 1528 differential expression genes (DEGs) were identified by transcriptomics analyses, including 725 up-regulated and 803 down-regulated. Further, we obtained 64 significantly DEGs including ...
Our results are the first to demonstrate the landscape of chromatin accessibility in GHPA, which may contribute to illustrate the underlying transcriptional regulation mechanism of this disease....
Current studies on the effect of high growth hormone (GH)/insulin-like growth factor (IGF)-1 on thyroid function are inconsistent. The aim was to explore the effect and potential mechanism of high GH/...
This was a retrospective cross-sectional study. Demographic and clinical data of 351 patients with GHPA who were first admitted to Beijing Tiantan Hospital, Capital Medical University, from 2015 to 20...
GH was negatively correlated with total thyroxine (TT4), free thyroxine (FT4), and thyroid-stimulating hormone (TSH). IGF-1 was positively correlated with total triiodothyronine (TT3), free triiodothy...
The study emphasized the complex interaction between the GH and the thyroid axes in patients with GHPA and highlighted the potential effect of glycemic status and tumor volume on thyroid function....
Few studies reported the effects of growth hormone-secreting pituitary adenoma (GHPA) on uric acid (UA) metabolism and the relationship between growth hormone (GH)/insulin-like growth factor-1 (IGF-1)...
A longitudinal study of 424 GHPA patients presenting to Beijing Tiantan Hospital, Capital Medical University between January 2015 and January 2023 was conducted. Spearman's correlation tests were perf...
At baseline, male patients, the lower the age, the higher the IGF-1 and body mass index (BMI), and the higher the UA levels. IGF-1 was significantly associated with UA after controlling for sex, age, ...
In patients with GHPA, UA levels are associated with disease activity. Changes in UA levels should be taken into account in the comprehensive treatment of GHPA, patients presenting with HUA should be ...
The objective of this study was to compare the cost-effectiveness of preoperative octreotide therapy followed by surgery versus the standard treatment modality for growth-hormone secreting pituitary a...
We developed an individual-level state-transition microsimulation model to simulate costs and outcomes associated with preoperative octreotide therapy followed by surgery and direct surgery for patien...
Under base case assumptions, direct surgery was found to be the dominant strategy as it yielded lower costs and greater health effects (QALYs) compared to preoperative octreotide strategy in the secon...
Using standard benchmarks for cost-effectiveness in the US ($100,000/QALY), preoperative octreotide therapy followed by surgery may not be cost-effective compared to direct surgery for patients with g...
Many patients with growth hormone-secreting pituitary adenoma (GHPA) fail to achieve biochemical remission, warranting investigation into epigenetic and molecular signatures associated with tumorigene...
DNA methylation levels were measured in 52 surgically resected tumors (37 NFPA, 15 GHPA) at ~100,000 known MAX binding sites derived using ChIP-seq analysis from ENCODE. Findings were correlated with ...
GHPA had more hypomethylation events across all known MAX binding sites. Of binding sites defined using ChIP-seq analysis, 1,551 sites had significantly different methylation patterns between the two ...
GHPA have significantly different DNA methylation and downstream protein expression levels of MAX compared to NFPA. These differences may influence mechanisms involved with cellular proliferation, tum...
Endonasal resection is the first-line treatment for patients harboring growth hormone (GH)-secreting pituitary adenomas. The complexity of the parasellar neurovascular structures makes pre-operative d...
A systematic review following the PRISMA statement was performed in July 2021....
Thirty-three studies were evaluated. Elevated GH and insulin-like growth factor-1 (IGF-1) levels are linked to the occurrence of cardiovascular risk factors. This is attributed to endothelial dysfunct...
There is an association between acromegaly and endothelial dysfunction, which increases cardiovascular risk factors and vascular anomalies. Preoperative vascular imaging, e.g., CT angiography, should ...
Cytotoxic T lymphocyte-associated protein 4 (CTLA4), a negative regulator typically expressed on the surface of T lymphocytes, is targeted by immunotherapy in patients with an ever-expanding spectrum ...
A case report describing a finding of concurrent growth hormone-producing pituitary adenoma and a radiologic evidence of Rathke's cleft cyst(RCC) in a middle-aged female is presented. We reviewed the ...
Growth hormone-secreting pituitary adenomas (GH-PAs) with a low Knosp grade are typically associated with a good postoperative biochemical remission (BR) rate. However, a proportion of patients do not...
In this retrospective study, we enrolled 140 patients who were diagnosed with lower Knosp (0-2) GH-PAs and received trans-sphenoidal surgery between December 2016 and June 2021 from the largest pituit...
One hundred and thirty six patients (97.1%) achieved gross total resection. The postoperative long-term BR was 68.6%. Empty sella, tumor maximum diameter and postoperative GH levels were independent f...
Early postoperative GH levels can be used as predictors of remission. However, BR was not associated with preoperative somatostatin analogs therapy or Knosp grade (0-2). For patients without residual ...
